Jove
Visualize
Contact Us

Related Experiment Videos

Rheumatoid arthritis: current concepts and management, Part 2.

L P Sterling

    American Pharmacy
    |September 1, 1990
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Beta adrenergic agonists.

    AACN clinical issues·1995
    Same author

    Drug therapy in an aging population.

    The Journal of practical nursing·1993
    Same author

    The clinical management of gout.

    American pharmacy·1991
    Same author

    Rheumatoid arthritis: current concepts and management, Part 1.

    American pharmacy·1990
    Same author

    Influence of an antacid containing aluminum and magnesium on the pharmacokinetics of cefixime.

    Antimicrobial agents and chemotherapy·1989
    Same journal

    Genetically engineered vaccines.

    American pharmacy·1995
    Same journal

    GAO report on need for a third class: 'prove it'.

    American pharmacy·1995
    Same journal

    Treatment of community-acquired urinary tract infections.

    American pharmacy·1995
    Same journal

    Liability and the changing role of pharmacists.

    American pharmacy·1995
    Same journal

    Dispensing errors and counseling in community practice.

    American pharmacy·1995
    Same journal

    Avoiding liability problems. American Pharmaceutical Association.

    American pharmacy·1995
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Rheumatoid arthritis (RA) management involves NSAIDs and conservative therapies. For severe cases, disease-modifying antirheumatic drugs (DMARDs) are used, balancing efficacy against significant side effects.

    Area of Science:

    • Rheumatology
    • Immunology
    • Pharmacology

    Background:

    • Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder primarily affecting joints.
    • Initial management often includes conservative non-drug therapies and nonsteroidal anti-inflammatory drugs (NSAIDs).

    Observation:

    • For patients with progressive or unresponsive disease, slow-acting antirheumatic drugs (SAARDs) are indicated.
    • SAARDs carry significant and frequent adverse effects, necessitating careful risk-benefit assessment.
    • Established SAARDs include gold compounds, antimalarials, and penicillamine, with sulfasalazine emerging for early RA.
    • Methotrexate is FDA-approved for RA, considered after initial therapies fail.
    • Cytotoxic agents like azathioprine and cyclophosphamide are reserved for severe RA due to malignancy risks.
    • Potent agents such as chlorambucil and cyclosporin A are options for refractory RA.

    Related Experiment Videos

  • Corticosteroids are used short-term as adjunctive or intra-articular therapy for refractory cases.

    • Findings:

    • The choice of SAARD depends on the individual patient's risk-to-benefit profile.
    • The optimal timing for initiating SAARDs (early RA) and their combination use remains a subject of controversy.

    Implications:

    • Understanding the spectrum of RA therapies, from conservative measures to potent immunosuppressants, is crucial for effective patient management.
    • Careful consideration of drug toxicity and efficacy is paramount in tailoring treatment strategies for rheumatoid arthritis.
    • Further research may clarify the controversial aspects of early and combination SAARD therapy in RA.